{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:20:51Z","timestamp":1782915651033,"version":"3.54.5"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The last several years have seen an emergence of literature documenting the utility of combination antimicrobial therapy, particularly in the salvage of refractory methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Recent clinical data are shaping conundrums of which regimens may be more beneficial, which can be potentially harmful, and which subset of patients stand to benefit from more aggressive treatment regimens than called for by current standards. In addition, the incorporation of combination therapy for MRSA bacteremia should be accompanied by the reminder that antimicrobial therapy does not need to be uniform for the entire duration, with an early intensive phase in high inoculum infections (eg, with combination therapy), followed by a consolidation phase (ie, monotherapy). This review and perspective consolidates the recent data on this subject and directs future goals in filling the knowledge gaps to methodically move forward towards improving patient outcomes.<\/jats:p>","DOI":"10.1093\/cid\/ciab452","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:19:47Z","timestamp":1620933587000},"page":"2353-2360","source":"Crossref","is-referenced-by-count":68,"title":["Current Paradigms of Combination Therapy in Methicillin-Resistant <i>Staphylococcus aureus<\/i> (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?"],"prefix":"10.1093","volume":"73","author":[{"given":"Warren","family":"Rose","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fantl","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Geriak","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sharp Memorial Hospital, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Nizet","sequence":"additional","affiliation":[{"name":"Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection and Inflammation, University of California-San Diego School of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection and Inflammation, University of California-San Diego School of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,16]]},"reference":[{"key":"2022020902090352100_CIT0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2022020902090352100_CIT0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2022020902090352100_CIT0003","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jac\/dkv368","article-title":"When sepsis persists: a review of MRSA bacteraemia salvage therapy","volume":"71","author":"Kullar","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022020902090352100_CIT0004","article-title":"Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus.","author":"Machado","year":"2020","journal-title":"bioRxiv"},{"key":"2022020902090352100_CIT0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"2022020902090352100_CIT0006","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jac\/dkh350","article-title":"Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus","volume":"54","author":"Adhikari","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2022020902090352100_CIT0007","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1128\/AAC.43.10.2565","article-title":"Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam","volume":"43","author":"Backo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0008","doi-asserted-by":"crossref","first-page":"e01634-16","DOI":"10.1128\/AAC.01634-16","article-title":"Molecular bases determining daptomycin resistance-mediated resensitization to beta-lactams (seesaw effect) in methicillin-resistant Staphylococcus aureus","volume":"61","author":"Renzoni","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0009","doi-asserted-by":"crossref","first-page":"e01554-17","DOI":"10.1128\/AAC.01554-17","article-title":"Outcomes of vancomycin plus a beta-lactam versus vancomycin only for treatment of methicillin-resistant Staphylococcus aureus Bacteremia","volume":"62","author":"Truong","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/phar.2034","article-title":"Early administration of adjuvant \u03b2-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis","volume":"37","author":"Casapao","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2022020902090352100_CIT0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0012","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/AAC.48.8.2871-2875.2004","article-title":"Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus","volume":"48","author":"Rand","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.02071-15","article-title":"Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for \u03b2-lactam-daptomycin synergy","volume":"60","author":"Berti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0015","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1128\/JB.00011-12","article-title":"Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins","volume":"194","author":"Pogliano","year":"2012","journal-title":"J Bacteriol"},{"key":"2022020902090352100_CIT0016","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1128\/AAC.00594-13","article-title":"\u03b2-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus","volume":"57","author":"Berti","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0017","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/AAC.00487-10","article-title":"Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the \u201cseesaw effect\u201d)","volume":"54","author":"Yang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0018","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.02192-12","article-title":"Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant \u03b2-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment","volume":"57","author":"Moise","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz746","article-title":"Daptomycin plus \u03b2-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","volume":"71","author":"Jorgensen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0020","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/phar.2437","article-title":"Combination of vancomycin or daptomycin and beta-lactam antibiotics: a meta-analysis","volume":"40","author":"Kale-Pradhan","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2022020902090352100_CIT0021","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40121-020-00292-8","article-title":"Monotherapy with vancomycin or daptomycin versus combination therapy with \u03b2-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective cohort analysis","volume":"9","author":"Alosaimy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2022020902090352100_CIT0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00109-013-1100-7","article-title":"Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus","volume":"92","author":"Sakoulas","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"2022020902090352100_CIT0023","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.30.4.375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens","volume":"30","author":"Steed","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2022020902090352100_CIT0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0025","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0026","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2022020902090352100_CIT0027","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/jac\/dkz253","article-title":"Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report","volume":"74","author":"Duss","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022020902090352100_CIT0028","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2022020902090352100_CIT0029","doi-asserted-by":"crossref","first-page":"e02483-18","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0030","doi-asserted-by":"crossref","first-page":"e00900-19","DOI":"10.1128\/AAC.00900-19","article-title":"Is daptomycin plus ceftaroline associated with better clinical outcomes than standard of care monotherapy for Staphylococcus aureus bacteremia?","volume":"63","author":"Kalil","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2022020902090352100_CIT0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jgar.2017.05.022","article-title":"In vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin and fusidic acid against MRSA strains","volume":"10","author":"Aktas","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"2022020902090352100_CIT0033","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00502-12","article-title":"Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics","volume":"56","author":"Berti","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0034","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/jac\/dkz194","article-title":"Metabolic interventions for the prevention and treatment of daptomycin non-susceptibility in Staphylococcus aureus","volume":"74","author":"Reed","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022020902090352100_CIT0035","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00584-11","article-title":"Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model","volume":"55","author":"Poeppl","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0036","doi-asserted-by":"crossref","first-page":"e02633-17","DOI":"10.1128\/AAC.02633-17","article-title":"The combination of daptomycin and fosfomycin has synergistic, potent, and rapid bactericidal activity against methicillin-resistant Staphylococcus aureus in a rabbit model of experimental endocarditis","volume":"62","author":"Garcia-de-la-Maria","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0037","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Mir\u00f3","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0038","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. a randomized clinical trial","volume":"72","author":"Pujol","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0039","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2022020902090352100_CIT0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/jama.2019.21472","article-title":"Combination therapy for methicillin-resistant Staphylococcus aureus bacteremia: not ready for prime time","volume":"323","author":"Gandhi","year":"2020","journal-title":"JAMA"},{"key":"2022020902090352100_CIT0041","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/cid\/cix675","article-title":"Increasing Evidence of the nephrotoxicity of piperacillin\/tazobactam and vancomycin combination therapy-what is the clinician to do?","volume":"65","author":"Watkins","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0042","doi-asserted-by":"crossref","first-page":"e01816-17","DOI":"10.1128\/AAC.01816-17","article-title":"Systematic review and meta-analysis of the safety of antistaphylococcal penicillins compared to cefazolin","volume":"62","author":"Eljaaly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0043","doi-asserted-by":"crossref","first-page":"S281-S","DOI":"10.1093\/ofid\/ofx163.631","article-title":"Combination vancomycin\/cefazolin (VAN\/CFZ) for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)","volume":"4","author":"Trinh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2022020902090352100_CIT0044","doi-asserted-by":"crossref","first-page":"ofz079","DOI":"10.1093\/ofid\/ofz079","article-title":"The impact of concomitant empiric cefepime on patient outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections treated with vancomycin","volume":"6","author":"Zasowski","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022020902090352100_CIT0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"\u03b2-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0046","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/dmd.112.049569","article-title":"Organic anion transporter 3 interacts selectively with lipophilic \u03b2-lactam antibiotics","volume":"41","author":"Wolman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"2022020902090352100_CIT0047","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2017.02.025","article-title":"Vancomycin induces reactive oxygen species-dependent apoptosis via mitochondrial cardiolipin peroxidation in renal tubular epithelial cells","volume":"800","author":"Sakamoto","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"2022020902090352100_CIT0048","doi-asserted-by":"crossref","first-page":"R1177","DOI":"10.1016\/j.cub.2017.09.015","article-title":"The origin and diversification of mitochondria","volume":"27","author":"Roger","year":"2017","journal-title":"Curr Biol"},{"key":"2022020902090352100_CIT0049","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/cid\/ciz686","article-title":"Interleukin (IL)-1\u03b2 and IL-10 host responses in patients with Staphylococcus aureus bacteremia determined by antimicrobial therapy","volume":"70","author":"Volk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0050","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/infdis\/jis552","article-title":"Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia","volume":"206","author":"Rose","year":"2012","journal-title":"J Infect Dis"},{"key":"2022020902090352100_CIT0051","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/cid\/cix157","article-title":"Increased endovascular Staphylococcus aureus inoculum is the link between elevated serum interleukin 10 concentrations and mortality in patients with bacteremia","volume":"64","author":"Rose","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0052","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/cid\/ciy739","article-title":"A prognostic model of persistent bacteremia and mortality in complicated Staphylococcus aureus bloodstream infection","volume":"68","author":"Guimaraes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0053","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/CCM.0000000000001465","article-title":"A dysregulated balance of proinflammatory and anti-inflammatory host cytokine response early during therapy predicts persistence and mortality in Staphylococcus aureus bacteremia","volume":"44","author":"Minejima","year":"2016","journal-title":"Crit Care Med"},{"key":"2022020902090352100_CIT0054","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.cell.2020.07.040","article-title":"Mortality risk profiling of Staphylococcus aureus bacteremia by multi-omic serum analysis reveals early predictive and pathogenic signatures","volume":"182","author":"Wozniak","year":"2020","journal-title":"Cell"},{"key":"2022020902090352100_CIT0055","doi-asserted-by":"crossref","first-page":"e00496-19","DOI":"10.1128\/AAC.00496-19","article-title":"Bicarbonate resensitization of methicillin-resistant Staphylococcus aureus to beta-lactam antibiotics","volume":"63","author":"Ersoy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0056","doi-asserted-by":"crossref","first-page":"e02072-19","DOI":"10.1128\/AAC.02072-19","article-title":"Ability of bicarbonate supplementation to sensitize selected methicillin-resistant Staphylococcus aureus strains to beta-lactam antibiotics in an ex vivo simulated endocardial vegetation model","volume":"64","author":"Rose","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0057","doi-asserted-by":"crossref","first-page":"e02445-19","DOI":"10.1128\/AAC.02445-19","article-title":"Scope and predictive genetic\/phenotypic signatures of bicarbonate (NaHCO3) responsiveness and beta-lactam sensitization in methicillin-resistant Staphylococcus aureus","volume":"64","author":"Ersoy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020902090352100_CIT0058","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2022020902090352100_CIT0059","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022020902090352100_CIT0060","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/cid\/ciz112","article-title":"Changing characteristics of Staphylococcus aureus bacteremia: results from a 21-year, prospective, longitudinal study","volume":"69","author":"Souli","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab452\/41392564\/ciab452.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/12\/2353\/42422283\/ciab452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/12\/2353\/42422283\/ciab452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T02:37:32Z","timestamp":1644374252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/12\/2353\/6276527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,16]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,5,16]]},"published-print":{"date-parts":[[2021,12,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab452","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,15]]},"published":{"date-parts":[[2021,5,16]]}}}